Comparison of the efficacy and safety of different dose anlotinib in combination with immune checkpoint inhibitors for patients with advanced non-small cell lung cancer
Preprint in Research Square (June 2024)
The most recent citing publications are shown below. View all 18 publications that cite this research output on Dimensions.
Anlotinib enhanced CD8+ T cell infiltration via induction of CCL5 improves the efficacy of PD-1/PD-L1 blockade therapy in lung cancer
Article in Cancer Letters (April 2024)
Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study
Article in Lung Cancer Targets and Therapy (March 2024)